Nilotinib, a potent and selective BCR-ABL inhibitor, is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study

Francis Joseph Giles

Nilotinib, a potent and selective BCR-ABL inhibitor, is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study

Francis Joseph Giles

Medicine

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

Original language	English (Ireland)
Journal	Blood
Publication status	Published - 1 Jan 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Authors (Note for portal: view the doc link for the full list of authors)

Authors
Kantarjian, H.M., Giles, F.J., Bhalla, K.P., Pinilla, J., Larson, R.A., Gattermann, N., Ottmann, O., Hochhaus, A., Radich, J.P., Saglio, G., Hughes, T.P., Martinelli, G., Kim, D.W., Shou, Y., Gallagher, N.J., Blakesley, R., Baccarani, M., Cortes, J., le Coutre, P.D.

Cite this

@article{3bcee38d0c0f499ba1b3308b0d4991a2,

title = "Nilotinib, a potent and selective BCR-ABL inhibitor, is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study",

author = "Giles, \{Francis Joseph\}",

year = "2010",

month = jan,

day = "1",

language = "English (Ireland)",

journal = "Blood",

}